Added to YB: 2026-10-15
Pitch date: 2026-10-12
LQDA [bullish]
Liquidia Corporation
+28.62%
current return
Author Info
Trade Ideas Flow is an Ex-Equity PM & Quant (10y+ buy-side) curating the Open-Web Hedge Fund. Reading 100s of pitches weekly to find the signal. Sign up for the newsletter.
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$2.5B
Pitch Price
$27.04
Price Target
93.36 (+168%)
Dividend
N/A
EV/EBITDA
13.88
P/E
18.72
EV/Sales
5.27
Sector
Pharmaceuticals
Category
special_situation
LQDA: finer powder, higher doses
LQDA (update): Liquidia’s collapse from $70.69 to roughly $28 may price in withdrawal of Yutrepia even though the infringed patent covers PH-ILD, not PAH. A conservative PAH-only sensitivity yields $42.10 at 10x EPS using current realized revenue per patient, but requires patients to double to 5,200. The decisive risk is a final judgment resetting approval for both indications, an outcome excluded from every valuation scenario.
Read full article (3 min)